The global beclomethasone dipropionate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is accelerating the growth of the market includes the rise in inflammatory-related symptoms among people. People living in industrial areas are more prone to developing asthma and allergic rhinitis, and beclomethasone dipropionate is used for the treatment of such diseases. Beclomethasone dipropionate is a synthetic corticosteroid drug used for controlling inflammatory symptoms such as sneezing, and shortness of breath. It is used by patients suffering from various inflammatory conditions including asthma, allergic rhinitis, and dermatoses. It is available in different formulations for its administration through oral, intranasal, and topical.
The global beclomethasone dipropionate market analysis includes some of the key market players such as Avik Pharmaceutical Ltd., Cipla Inc., and Teva Pharmaceutical Industries Ltd., among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in February 2018, Teva Pharmaceutical Industries Ltd. announced that QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is commercially available to patients in both 40 mcg and 80 mcg strengths by prescription in the US.
Market Coverage
Competitive Landscape: Avik Pharmaceutical Ltd., Cipla Inc., and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Beclomethasone Dipropionate Market by Segment
By Application
• Asthma
• Allergic Rhinitis
By Route of Administration
• Injection
• Oral
• Inhalation
Global Beclomethasone Dipropionate Market by Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World